Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved prescription drugs for dermatological conditions, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is set to take place on Wednesday, October 9, 2024, in New York City.
Members of Journey Medical's management team will be attending one-on-one meetings during the conference. This participation highlights the company's commitment to engaging with investors and industry professionals in the healthcare sector.
The conference provides an opportunity for Journey Medical to showcase its focus on selling and marketing dermatological treatments, potentially attracting investor interest and fostering business relationships within the pharmaceutical industry.
Journey Medical (Nasdaq: DERM), un'azienda farmaceutica in fase commerciale specializzata in farmaci da prescrizione approvati dalla FDA per condizioni dermatologiche, ha annunciato la sua partecipazione alla 3a Conferenza Annuale ROTH sulle Opportunità Sanitarie. L'evento si terrà il mercoledì 9 ottobre 2024, a New York City.
I membri del team di gestione di Journey Medical parteciperanno a incontri one-to-one durante la conferenza. Questa partecipazione sottolinea l'impegno dell'azienda nel coinvolgere investitori e professionisti del settore sanitario.
La conferenza offre a Journey Medical l'opportunità di mettere in mostra il suo focus sulla vendita e sul marketing dei trattamenti dermatologici, potenzialmente attirando l'interesse degli investitori e favorendo relazioni commerciali all'interno dell'industria farmaceutica.
Journey Medical (Nasdaq: DERM), una empresa farmacéutica en fase comercial especializada en medicamentos recetados aprobados por la FDA para condiciones dermatológicas, ha anunciado su participación en la 3ª Conferencia Anual ROTH sobre Oportunidades en Salud. El evento se llevará a cabo el miércoles 9 de octubre de 2024, en la ciudad de Nueva York.
Miembros del equipo de gestión de Journey Medical asistirán a reuniones uno a uno durante la conferencia. Esta participación destaca el compromiso de la empresa en relacionarse con inversores y profesionales de la industria de la salud.
La conferencia proporciona una oportunidad para que Journey Medical muestre su enfoque en la venta y marketing de tratamientos dermatológicos, lo que podría atraer el interés de los inversores y fomentar relaciones comerciales dentro de la industria farmacéutica.
Journey Medical (Nasdaq: DERM)는 FDA 승인 처방약을 전문으로 하는 상업 단계의 제약 회사로, 피부 질환을 위한 약품을 제공합니다. 이번에 제3회 ROTH 헬스케어 기회 콘퍼런스에 참가할 것이라고 발표했습니다. 이 행사는 2024년 10월 9일 수요일, 뉴욕 시에서 열릴 예정입니다.
Journey Medical의 경영 관리 팀 구성원들은 콘퍼런스 기간 동안 일대일 미팅에 참석할 예정입니다. 이번 참여는 투자자 및 헬스케어 전문가와의 소통에 대한 회사의 의지를 강조합니다.
이번 콘퍼런스는 Journey Medical이 피부 질환 치료제를 판매 및 마케팅하는 데 중점을 두고 있음을 보여줄 수 있는 기회를 제공하며, 잠재적으로 투자자의 관심을 끌고 제약 산업 내 비즈니스 관계를 촉진할 수 있습니다.
Journey Medical (Nasdaq: DERM), une entreprise pharmaceutique en phase commerciale spécialisée dans les médicaments prescrits approuvés par la FDA pour les affections dermatologiques, a annoncé sa participation à la 3ème Conférence Annuelle ROTH sur les Opportunités de Santé. L'événement se déroulera le mercredi 9 octobre 2024, à New York.
Des membres de l'équipe de direction de Journey Medical assisteront à des rencontres individuelles pendant la conférence. Cette participation met en avant l'engagement de l'entreprise à dialoguer avec les investisseurs et les professionnels du secteur de la santé.
La conférence offre à Journey Medical l'opportunité de mettre en valeur son accent sur la vente et le marketing des traitements dermatologiques, attirant potentiellement l'intérêt des investisseurs et favorisant les relations d'affaires au sein de l'industrie pharmaceutique.
Journey Medical (Nasdaq: DERM), ein pharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf von der FDA genehmigte verschreibungspflichtige Medikamente für dermatologische Erkrankungen spezialisiert hat, hat seine Teilnahme an der 3. Jahrestagung ROTH zu Gesundheitsmöglichkeiten bekannt gegeben. Die Veranstaltung findet am Mittwoch, den 9. Oktober 2024, in New York City statt.
Mitglieder des Managementteams von Journey Medical werden während der Konferenz an Einzelgesprächen teilnehmen. Diese Teilnahme unterstreicht das Engagement des Unternehmens, mit Investoren und Branchenfachleuten im Gesundheitssektor in Kontakt zu treten.
Die Konferenz bietet Journey Medical die Möglichkeit, sein Augenmerk auf den Verkauf und das Marketing dermatologischer Behandlungen zu präsentieren, wodurch potenziell Investoreninteresse geweckt und Geschäftsbeziehungen innerhalb der Pharmaindustrie gefördert werden könnten.
- None.
- None.
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical’s management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, scheduled to take place on Wednesday, October 9, 2024 in New York City.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When is Journey Medical (DERM) participating in the ROTH Healthcare Opportunities Conference?
Where will the 3rd Annual ROTH Healthcare Opportunities Conference be held?
What type of meetings will Journey Medical (DERM) attend at the conference?
What is the primary focus of Journey Medical (DERM)?
What is Journey Medical 's stock symbol?
